The trajectory of companies tied to Sildenafil's legacy presents a challenging investment scenario . While the initial surge generated substantial returns , generic copies have significantly diminished revenue. Investing in associated pharmaceutical companies now requires a thorough assessment of proprietary protection , evolving medical changes, a